MIC values with the bacterial inoculum automatically adjusted using a nephelometer (BD PhoenixSpec™ nephelometer) determining the turbidity of microbial suspensions equivalent to McFarland standards from 0.10 to 4.5.
There is a clear unmet medical need in the field of infectious diseases: infections caused by resistant bacteria. A major goal to fight resistant bacteria involves the design, discovery and development of new antibiotics particularly against multi-drug-resistant strains. Polymyxins, an old class of antimicrobial cyclic lipopeptides highly potent against therapeutically relevant Gram-negative bacteria, have been rescued and are now used only as last resort antibiotics in hospitals because of their nephrotoxicity and neurotoxicity that require careful monitoring of the patient. Our group has embarked in a project to design and develop new polymyxins devoid of toxicity problems using a versatile and chemically accessible scaffold structure. Compounds show a remarkable activity against Gram-negative bacteria. Herein, the last results of our recently designed polymyxin analogs will be presented.
Introduction
Figure:
General structure of designed compounds (canonical analog 1 is shown as an example). The structural features taken into account for the design of the analogs are highlighted. (Rabanal et al. 2015) Starting from our successful disulfide cyclopeptide scaffold (Rabanal et al. 2015) , we have recently designed a series of new compounds aiming at reducing toxicity by (see figure) :
shortening the fatty acid tail reducing basicity of amino groups increasing lability of the scaffold backbone by introducing isosteric bonds (i. e. disulfide or ester) to facilitate metabolization upon accumulation in kidneys to potentially lower renal toxicity.
The molecular mechanism of polymyxin toxicity is not well understood. It seems to be associated to the presence of the fatty acid tail and the cationic charges of the basic Dab side chain amino groups (Keirstead et al. 2013 ).
In fact, polymyxin B nonapeptide, a deacylated and truncated derivative of polymyxin B exhibits much lower toxic effects (Danner et al 1989) . In addition, the sulfomethylation of polymyxin reduces its acute toxicity (Barnett et al. 1947) .
Polymyxins accumulate in the kidney's cortical region and is metabolized with difficulty by renal detoxifying enzymes (Rabanal et al. 2017) .
Design Polymyxin Toxicity
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-It is possible to design highly active analogs with shorter fatty acid tail or lower overall cationic charge and having a more easily metabolizable scaffold to potentially lower toxicity. In vivo tests in mice are underway.
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